However, when analysed according to treatment received in this cohort, patients with EGFR CNG positive tumours who received neoadjuvant PBC had longer overall survival than patients with EGFR CNG positive tumours who did not receive neoadjuvant PBC (Fig. 1c). Here, EGFR is linked to neoplasm.